Skip to main content
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRS ISIN · US00461U1051 LEI · 5493000B2LQ9QTW1DF52 US Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2026-05-07 Interim / Quarterly Rep…
Country US United States of America
Listing US ACRS

About Aclaris Therapeutics, Inc.

https://www.aclaristx.com/

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel drug candidates for immuno-inflammatory diseases. The company leverages its core expertise in drug discovery, development, and kinase inhibition to create a pipeline of both small and large molecule drugs. Aclaris focuses on translating scientific discovery into innovative therapies to address the needs of patients with underserved conditions.

Recent filings

Filing Released Lang Actions
10-Q - Aclaris Therapeutics, Inc. (0001557746) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
Earnings Release Classification · 80% confidence The document is a Form 8-K Current Report filed under Item 2.02 ‘Results of Operations and Financial Condition,’ furnishing a press release announcing quarterly financial results for the period ended March 31, 2026. This corresponds to an initial announcement of periodical financial results, which falls under the Earnings Release category. Q1 2026
2026-05-07 English
8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 28, 2026. It announces a conference call to discuss clinical trial results and includes a presentation (Exhibit 99.1) and a press release (Exhibit 99.2). The document explicitly states that the presentation accompanies the conference call. The content focuses on disclosure of clinical trial results and an upcoming conference call, which aligns with a Call Transcript or related materials. However, the actual transcript is not included, only the presentation and press release are attached. Given the nature of the Form 8-K and the inclusion of a presentation for a conference call, the best fit is Investor Presentation (IP). The document is not a full transcript, annual or interim report, or other categories. The length is under 5,000 characters, but it contains substantive information and a presentation, not just a report publication announcement. Therefore, the classification is Investor Presentation (IP) with high confidence.
2026-04-28 English
ARS - Aclaris Therapeutics, Inc. (0001557746) (Filer)
Annual Report
2026-04-23 English
DEF 14A - Aclaris Therapeutics, Inc. (0001557746) (Filer)
Proxy Solicitation & Information Statement
2026-04-23 English
SCHEDULE 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)
Major Shareholding Notification
2026-03-26 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.